These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 24077403)

  • 21. Low mutational burden of eight genes involved in the MAPK/ERK, PI3K/AKT, and GNAQ/11 pathways in female genital tract primary melanomas.
    Pappa KI; Vlachos GD; Roubelakis M; Vlachos DE; Kalafati TG; Loutradis D; Anagnou NP
    Biomed Res Int; 2015; 2015():303791. PubMed ID: 25695059
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BRAF and NRAS mutations in melanoma and melanocytic nevi.
    Poynter JN; Elder JT; Fullen DR; Nair RP; Soengas MS; Johnson TM; Redman B; Thomas NE; Gruber SB
    Melanoma Res; 2006 Aug; 16(4):267-73. PubMed ID: 16845322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Constitutive activation of the mitogen-activated protein kinase signaling pathway in acral melanomas.
    Takata M; Goto Y; Ichii N; Yamaura M; Murata H; Koga H; Fujimoto A; Saida T
    J Invest Dermatol; 2005 Aug; 125(2):318-22. PubMed ID: 16098043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted therapy in melanoma.
    Kudchadkar RR; Smalley KS; Glass LF; Trimble JS; Sondak VK
    Clin Dermatol; 2013; 31(2):200-8. PubMed ID: 23438383
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure.
    Handolias D; Salemi R; Murray W; Tan A; Liu W; Viros A; Dobrovic A; Kelly J; McArthur GA
    Pigment Cell Melanoma Res; 2010 Apr; 23(2):210-5. PubMed ID: 20088873
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Molecular heterogeneity of malignant melanomas].
    Glatz K
    Pathologe; 2007 Nov; 28(6):474-8. PubMed ID: 17885757
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
    Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M
    Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological inhibitors of c-KIT block mutant c-KIT mediated migration of melanocytes and melanoma cells in vitro and in vivo.
    Posch C; Moslehi H; Sanlorenzo M; Green G; Vujic I; Panzer-Grümayer R; Rappersberger K; Ortiz-Urda S
    Oncotarget; 2016 Jul; 7(29):45916-45925. PubMed ID: 27322141
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [New therapies targeting the genetic mutations responsible for different types of melanoma].
    Botella-Estrada R; Sanmartín Jiménez O
    Actas Dermosifiliogr; 2010 Jun; 101(5):394-400. PubMed ID: 20525481
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advances in targeted therapy for melanoma.
    Friedlander P; Hodi FS
    Clin Adv Hematol Oncol; 2010 Sep; 8(9):619-27. PubMed ID: 21157411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting NRAS in melanoma.
    Kelleher FC; McArthur GA
    Cancer J; 2012; 18(2):132-6. PubMed ID: 22453013
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
    Yaman B; Akalin T; Kandiloğlu G
    Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic alterations in signaling pathways in melanoma.
    Haluska FG; Tsao H; Wu H; Haluska FS; Lazar A; Goel V
    Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2301s-2307s. PubMed ID: 16609049
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting mutant NRAS signaling pathways in melanoma.
    Vu HL; Aplin AE
    Pharmacol Res; 2016 May; 107():111-116. PubMed ID: 26987942
    [TBL] [Abstract][Full Text] [Related]  

  • 35. KIT and Melanoma: Biological Insights and Clinical Implications.
    Pham DDM; Guhan S; Tsao H
    Yonsei Med J; 2020 Jul; 61(7):562-571. PubMed ID: 32608199
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
    Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
    Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
    Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
    Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dermoscopic criteria associated with BRAF and NRAS mutation status in primary cutaneous melanoma.
    Pozzobon FC; Puig-Butillé JA; González-Alvarez T; Carrera C; Aguilera P; Alos L; Badenas C; Grichnik JM; Malvehy J; Puig S
    Br J Dermatol; 2014 Oct; 171(4):754-9. PubMed ID: 24749938
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Naturally Occurring Canine Melanoma as a Predictive Comparative Oncology Model for Human Mucosal and Other Triple Wild-Type Melanomas.
    Hernandez B; Adissu HA; Wei BR; Michael HT; Merlino G; Simpson RM
    Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29385676
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mitogen-Activated Protein Kinase Signaling Pathway in Cutaneous Melanoma: An Updated Review.
    Acosta AM; Kadkol SS
    Arch Pathol Lab Med; 2016 Nov; 140(11):1290-1296. PubMed ID: 27788045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.